You searched for "intravitreal"
The results of the last survey Apr25
Postoperative endophthalmitis is arguably the worse possible complication of cataract surgery. We are a victim of our own success as the procedure has such an amazing safety profile that when things go wrong patients are bound to feel aggrieved and...
Injection frequency and anatomic outcomes following conversion to Aflibercept in neovascular AMD patients
This is a retrospective study of patients with neovascular age-related macular degeneration (AMD) treated with intravitreal Lucentis and / or Avastin who were switched to aflibercept (Eylea). This study was carried out by the Casey Eye Institute retinal clinics, between...Update on emerging therapies for age-related macular degeneration
The 23rd European Society of Retina Specialists (EURETINA) Congress, held in Amsterdam, the Netherlands, provided a timely update on anti-complement therapy for geographic atrophy and emerging investigational therapies for neovascular age-related macular degeneration. Anti-complement therapy for geographic atrophy Geographic atrophy...Clinical trial investigates ‘Light Touch’ approach to wet AMD treatment
A clinical trial led by NIHR Moorfields Clinical Research Facility will explore a new ‘light-touch’ treatment approach for patients with neovascular age-related macular degeneration (wet AMD) that could result in fewer injections and reduced number of clinic visits. Funded by...Aspiration of anteriorly migrated dexamethasone implant using an 18G intravenous cannula
Intravitreal dexamethasone (Ozurdex 0.7mg) is a biodegradable, sustained-release implant used to manage diabetic macular oedema, macular oedema secondary to retinal vein occlusion, and non-infectious posterior uveitis due to its anti-inflammatory effects and VEGF suppression [1]. While effective, the implant may...
ESASO Course Series (Volume 3): Cataract
This book is designed as a course manual for cataract and refractive surgery. It starts off by discussing both the fluidics and dynamics of phacoemulsification, touching techniques and management of difficult scenarios. The ins and outs of conventional, accommodative, toric...Pathophysiology of diabetic macular oedema: why combination therapy may be better
The prevalence of diabetes has continued to increase over the years. It is currently estimated that there are 382 million with diabetes worldwide in 2013, and that this figure is expected to rise to 592 million by 2035 [1]. In...
Cytokine levels in vitreous fluid in patients with pathological myopia
Pathological myopia (PM) is a leading cause of irreversible visual impairment worldwide, and efforts are dedicated to the study of its underlying mechanisms. Axial extension of the eyeball is regulated via a cascade of biochemical molecules that are initiated in...
Variability between handheld fundus cameras
Handheld fundus cameras offer the potential of enhancing opportunities for telemedicine diagnosis of glaucoma, especially in underserved settings, as they are less bulky, inexpensive and don’t require skilled personnel compared to traditional table-mounted retinal cameras. This study aimed to compare...
VIBIM Study: One-year results of treatment of DME with aflibercept using TnE
The VIBIM study (the treat-and-extend regimen (TER) using intravitreal aflibercept in diabetic macular edema (DME) study) was designed to evaluate the efficacy of the TER using aflibercept in the management of DME for a period of two years. The authors...
Insights in resistant diabetic macular oedema
This article gives a bird’s eye review of the different modalities for the treatment of diabetic macular oedema (DME). The debut of anti-VEGFs has brought a paradigm shift in DME management. This treatment has now become a major breakthrough in...
